5
Participants
Start Date
May 31, 2012
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Ghrelin Group 1
The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Ghrelin Group 2
The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Clinical and Translational Research Center, University of Pennsylvania, Philadelphia
University of Pennsylvania
OTHER